Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 participants, all of whom completed the study — none dropped out. Every participant received a dexamethasone pellet (a small implant that slowly releases a steroid medication into the eye). The trial was measuring eye inflammation, specifically looking at whether signs of inflammation inside the eye — such as cells in the front chamber of the eye, cloudiness in the gel-like interior, or inactive lesions at the back of the eye — were absent at 6 and 12 months after treatment. The reported data shows that at the 6-month mark (the main thing being measured), 12 out of 20 participants had no detectable signs of intraocular (inside-the-eye) inflammation. At 12 months (a secondary measurement), 13 out of 20 participants showed an absence of those inflammation signs. The trial also tracked eye pressure (the fluid pressure inside the eye, measured in mmHg). The reported data shows average eye pressure readings across visits of 13.2, 18.2, 14.6, 14.1, and 13.5 mmHg respectively — noting that the second reading was higher than the others. Regarding cataract development (clouding of the eye's lens), the reported data shows that across the earlier time points no participants needed cataract surgery, but by the later visits, 1 and then 3 eyes across the group had progressed to needing cataract surgery. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have active uveitis (inflammation inside the eye) affecting the middle or back of the eye that is serious enough to threaten your vision, and your doctor is planning to treat it with strong steroid medicines along with other immune-suppressing drugs.
- You are already taking immune-suppressing medication but still need high-dose steroids to control your eye inflammation (this is still acceptable).
- You are 18 years of age or older and are willing to sign a consent form agreeing to take part.
- The inside of your eye is clear enough for the study team to take special eye photographs and scans (called OCT and fundus photography).
- You do not have any planned non-urgent eye surgery scheduled within the first 3 months of joining the trial.
Who may not be able to join:
- Your uveitis is caused by an infection.
- You have a history of scleritis (inflammation of the white outer wall of the eye).
- You currently have or are suspected to have a viral infection affecting the surface of your eye.
- You have a history of tuberculosis, other mycobacterial infections, or fungal disease.
- You are HIV positive.
- You are under 18 years old.
- You are allergic to dexamethasone (a type of steroid).
- Your eye pressure is currently not under control.
- You have severe glaucoma.
- You are missing your natural eye lens and have a damaged lens capsule inside your eye (confirm with trial site).
- You have an artificial lens implanted at the front of your eye along with a damaged lens capsule (confirm with trial site).
- The inside of your eye is too cloudy to allow the required eye photographs or scans to be taken.
- You have non-urgent eye surgery planned within 3 months of joining the trial.
- You have any whole-body (systemic) disease that requires you to take steroid medicines throughout your body.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Absence of Intraocular Inflammation at 6 Months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.